US 100 Cash CFD forum
NDX Trump announces 25 percent Aluminium and Steel import tariffs to start tomorrow. Is this goon trying to kill off the stock markets. I was bearish before but this is mental. Is he shorting too?NDX 191 points drop just before opening. What's caused that?
NAS100 buttcorn leading the charge
US100 current price dropped a lot after weekend 600 points.. feeling bad for long
NDX I have traded on minute charts and hourly charts.. I recommend 1hr chart frame
NAS100 🤫 The idea no 46In a time of confusion, here I am to help
Idea:Moustafa! 09.02.25 My analysis…
NAS100 what’s given you guys the confidence that next week’s fall will be just as same as the previous few weeks fall? Why will it not be a retracement and continue back up? I’m not predicting anything for the coming week because I don’t know and I will be shifting from swing trading to day trading attitude because of uncertainty but I’m interested in knowing the reason behind the confidence.NAS100 tariffs, mag7 with the worst collective quarter since 2021 compared to estimates, vix rising, inflation concerns.
LLY Eli Lilly's revenue soared 45% year-over-year to $13.5 billion, surpassing expectations by $100 million. This growth was fueled by strong sales of Mounjaro ($3.5 billion) and Zepbound ($1.9 billion), both aligning with pre-announced figures. Although sales fell short of initial projections in the previous quarter, the company's FY25 revenue guidance of $58-61 billion (+32% Y/Y) reassured investors. Management highlighted a planned 60% increase in GLP-1 supply during the first half of 2025 to meet rising demand, while the removal of Mounjaro and Zepbound from the FDA’s shortage list is expected to limit compounded alternatives and strengthen Lilly’s market dominance. With recent regulatory approvals for Kisunla and Ebglyss, expanded global rollouts for Mounjaro, and ongoing reimbursement negotiations for Zepbound, Lilly continues to reinforce its leadership in the obesity and diabetes space. Management remains optimistic about long-term growth, citing the need for further capacity expansion to keep pace with demand. The next major catalyst will be mid-year Phase 3 trial results for Orforglipron, Lilly’s oral obesity treatment.
SPX NDX 
DXY